Celine Halioua is the CEO and Founder of Loyal, a biotech startup developing drugs intended to help dogs live longer, healthier lives. At Loyal, Celine leads a team of neuroscientists, veterinarians, biologists, chemists, regulatory experts, creatives and operators to develop the first FDA-approved dog lifespan extension drug for veterinary use. If approved, the drug is expected to be the first drug ever approved for lifespan extension in any species. Since founding Loyal in 2019 at the age of 24, Celine has raised more than $125 million from top venture capitalists including Khosla Ventures, Bain Capital, First Round Capital, and Valor Equity Partners. Prior to Loyal, Celine attended Oxford University where she studied the economics of gene therapy with a focus on understanding the incentives of different healthcare systems in providing curative therapeutics. Her studies fed a broader interest in health equality that led her to longevity and preventative medicine. Celine then left Oxford to join Laura Deming at The Longevity Fund, one of the pioneering early investors in the longevity field. Celine has a B.S.A. in Neuroscience from the University of Texas.